VolitionRx Gets Lind Waiver for ATM Share Sales Above $10 Million Annual Cap
VolitionRx entered a waiver and consent with its lender Lind Global Asset Management XII on September 2, 2026. Lind agreed that all at-the-market (ATM) stock sales, including amounts above the $10 million annual cap, count as permitted sales and waived related default and remedy rights tied to those sales. The waiver removes a potential default risk for the company while it sells shares under its ATM program, but it also means share sales above the prior cap can proceed without the lender's objection.
Key points
- Lind consented to all ATM Agreement sales, including amounts above $10 million in a calendar year, as Permitted ATM Sales.
- Lind waived remedies tied to ATM sales under the Purchase Agreement and both Notes, including rights to accelerate amounts due.
- Conversion Price of the Notes and Exercise Price of the Warrants were adjusted for ATM sales through August 28, 2026; sales after that date are excluded from adjustment.
- The Notes are $7.5 million (May 15, 2025) and $2.4 million (January 7, 2026); the warrants cover 651,042 and 350,018 shares.
The filing
Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 02, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.